<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752020</url>
  </required_header>
  <id_info>
    <org_study_id>2020P002755</org_study_id>
    <nct_id>NCT04752020</nct_id>
  </id_info>
  <brief_title>Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty</brief_title>
  <official_title>Prospective Assessment of Whether Adjuvant Netarsurdil Use Improves Post-Operative Outcomes in Patients Undergoing Descemetorhexis Without Endothelial Keratoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective assessment of whether adjuvant Netarsudil use in patients&#xD;
      undergoing Descemetorhexis without endothelial keratoplasty improves time to corneal&#xD;
      clearance and post-operative central endothelial cell counts. The anticipated enrollment is&#xD;
      25 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects meeting inclusion criteria will be identified by Massachusetts Eye and Ear cornea&#xD;
      surgeons during their pre-operative assessment and invited to participate in the study.&#xD;
      Written informed consent will be obtained from the patient. The patients will then be added&#xD;
      to a shared Epic patient list with a shared to-do column (outside of the patient record)&#xD;
      indicating their subject ID and date of recruitment. All subjects will be asked to provide&#xD;
      their best contact phone number which will be updated in the chart.&#xD;
&#xD;
      Upon obtaining informed consent, subjects will receive a bottle of Netarsudil from the&#xD;
      Massachusetts Eye and Ear research pharmacy with post-operative instructions to use the drop&#xD;
      once a day at bedtime starting on post-operative day 1 . Each patient will then receive&#xD;
      regular, scheduled post-operative monitoring with a post-operative day 1 visit,&#xD;
      post-operative week 1 visit, post-operative month 1 visit, and then every 2 month follow up&#xD;
      for twelve months. Clinical examination, including best corrected visual acuity and&#xD;
      intraocular pressure, will be recorded during every visit. Corneal topography and specular&#xD;
      microscopy will be performed during the pre-operative assessment and during each bi-monthly&#xD;
      visit in order to monitor for post-operative outcomes.&#xD;
&#xD;
      A retrospective chart review will be performed prior to new patient enrollment for patients&#xD;
      who had previously had DWEK and did not receive a rho-kinase inhibitor. These patients will&#xD;
      be included for pre-operative and post-operative vision, pachymetry, corneal topography&#xD;
      results, and specular microscopy results with minimization of data acquisition as no informed&#xD;
      consent can be obtained from these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in central corneal pachymetry over time</measure>
    <time_frame>Measured at post-operative month one visit and then every 2 months for 1 year</time_frame>
    <description>Corneal thickness on clinical examination and corneal topography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in endothelial cell count over time</measure>
    <time_frame>Measured at post-operative month one visit and then every 2 months for 1 year</time_frame>
    <description>Central endothelial cell count by specular microscopy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Fuchs' Endothelial Dystrophy</condition>
  <arm_group>
    <arm_group_label>Netarsudil use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Netarsudil eye drops to use 1 drop nightly in the operative eye after DWEK surgery until corneal clearance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil Ophthalmic</intervention_name>
    <description>Use of netarsudil after Descemetorhexis without endothelial keratoplasty</description>
    <arm_group_label>Netarsudil use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fuchs corneal dystrophy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Other corneal eye diseases&#xD;
&#xD;
          -  Non-compliance with netarsudil&#xD;
&#xD;
          -  Intolerance of netarsudil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emma Davies, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sila E Bal, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emma Davies, MD</last_name>
    <phone>617-523-7900</phone>
    <email>emma_davies@meei.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Davies, MD</last_name>
      <phone>610-299-2673</phone>
      <email>emma_davies@meei.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sila Bal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>March 28, 2021</last_update_submitted>
  <last_update_submitted_qc>March 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Emma C. Davies, MD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Descemetorhexis without endothelial keratoplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

